Partners

LUMICKS Logo Grey

Lumicks
Expertise Partner

LUMICKS creates instruments for dynamic single-molecule and cell avidity analysis. Our latest instrument, the z-Movi® Cell Avidity Analyzer, enables the measurement and selection of immune cells based on their interactions with cancer cells, providing a new parameter for experimentally evaluating immune cell functionality and activation.

Recent studies have revealed that the overall binding strength (or avidity) between T cells and tumour cells represents a crucial parameter for identifying and developing potent cancer immunotherapies. Cell avidity is driven by a multitude of factors, including receptor density, affinity the engagement of co-receptors and, if used, T-cell engagers. Whether exploring NK or CAR-T function, cellular avidity is providing new insights into downstream events and therapeutic effectiveness. Compared with affinity, cell avidity provides a more complete and physiologically relevant picture that reflects the live interaction between T cells and tumour cells.

One of the main obstacles in measuring avidity is the lack of fast, specific, and accurate technologies. The z-Movi® Cell Avidity Analyzer is a novel and unique instrument for direct measurement of cell–cell interaction strength using acoustic forces. This new technology provides predictive, reproducible and fast high-throughput results at a single-cell level.

Visit: www.lumicks.com

evorion_bio_300PPI

evorion biotechnologies
Innovation Partner

evorion biotechnologies has developed its innovative CellCity System that enables multi-modal analysis of thousands of cell-cell interactions in a 3D microenvironment at single-cell resolution and offers custom development services to access evorion´s unique, proprietary functional phenomics workflow. For the first time, researchers can connect a single cell’s dynamic and functional phenotype with underlying multi-omics data, enabling novel insights into cancer-immune cell interactions that will boost translational research and developments in adoptive cell therapy.

Visit: www.evorion.de